The OPEN MINDS Executive Blueprint for Crisis ManagementBuilding Organizational Sustainability & Success in a Disrupted Health & Human Service Market
A 32-week program designed to help executive teams navigate the business, organizational, operational, and culture changes of a market in turbulence. The program, based on the seven-component OPEN MINDS executive blueprint, combines a series of 35 live educational web briefings with online technical assistance and a suite of on-demand resources.
FDA Releases Model Drug Facts Labeling For Over-The-Counter Naloxone
On January 17, 2019, the U.S. Food and Drug Administration (FDA) released model drug facts labeling (DFL) to support the development of over-the-counter (OTC) versions of naloxone to reverse opioid overdoses. In the announcement, the FDA said this is the first time it has proactively developed and tested a DFL for a drug to support development of an OTC product. The model DFL otherwise contains all the key information needed for an untrained bystander to administer naloxone. The goal is to encourage pharmaceutical companies to enter the OTC naloxone market. Any sponsors can use the model DFL . . .